Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 8.24
(-2.94%)
SEK 8.24
(-2.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -140.85 Million SEK | -27.68% |
| 2023 | -110.97 Million SEK | -5.37% |
| 2022 | -95.89 Million SEK | -26.94% |
| 2021 | -85.29 Million SEK | -900.28% |
| 2020 | -33.28 Million SEK | 128.58% |
| 2019 | -36.34 Million SEK | 16.67% |
| 2018 | -43.82 Million SEK | -71.85% |
| 2017 | -25.41 Million SEK | -37.87% |
| 2016 | -31.9 Million SEK | 14.54% |
| 2015 | -21.54 Million SEK | -29.58% |
| 2014 | -16.62 Million SEK | -29.1% |
| 2013 | -12.87 Million SEK | 72.18% |
| 2012 | -16.11 Million SEK | -141.41% |
| 2011 | 111.76 Million SEK | 4180.58% |
| 2010 | -2.73 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -45.07 Million SEK | -16.71% |
| 2024 Q3 | -39.85 Million SEK | -41.1% |
| 2024 Q2 | -28.47 Million SEK | 7.67% |
| 2024 Q1 | -29.88 Million SEK | 17.77% |
| 2023 Q1 | -31.73 Million SEK | -20.16% |
| 2023 FY | - SEK | -5.37% |
| 2023 Q4 | -36.19 Million SEK | -86.22% |
| 2023 Q3 | -19.43 Million SEK | 18.4% |
| 2023 Q2 | -23.82 Million SEK | 24.93% |
| 2022 Q4 | -26.4 Million SEK | -59.31% |
| 2022 FY | - SEK | -26.94% |
| 2022 Q3 | -16.57 Million SEK | 6.79% |
| 2022 Q2 | -17.78 Million SEK | 52.25% |
| 2022 Q1 | -37.24 Million SEK | -131.53% |
| 2021 Q1 | -12.71 Million SEK | -1.1% |
| 2021 Q2 | -11.81 Million SEK | 7.08% |
| 2021 Q3 | -32.32 Million SEK | -173.62% |
| 2021 FY | - SEK | -900.28% |
| 2021 Q4 | 118.12 Million SEK | 465.49% |
| 2020 Q1 | -6.7 Million SEK | 30.69% |
| 2020 Q3 | -7.01 Million SEK | -119.11% |
| 2020 Q4 | -12.57 Million SEK | -79.37% |
| 2020 Q2 | 36.67 Million SEK | 646.71% |
| 2020 FY | - SEK | 128.58% |
| 2019 Q4 | -9.68 Million SEK | -23.16% |
| 2019 Q1 | -8.43 Million SEK | 24.52% |
| 2019 FY | - SEK | 16.67% |
| 2019 Q2 | -10.37 Million SEK | -23.04% |
| 2019 Q3 | -7.86 Million SEK | 24.25% |
| 2018 Q3 | -12.55 Million SEK | -37.99% |
| 2018 FY | - SEK | -71.85% |
| 2018 Q4 | -11.17 Million SEK | 11.0% |
| 2018 Q2 | -9.09 Million SEK | 15.74% |
| 2018 Q1 | -10.79 Million SEK | -71.37% |
| 2017 FY | - SEK | -37.87% |
| 2017 Q4 | -6.3 Million SEK | 23.93% |
| 2017 Q1 | -4.41 Million SEK | 8.46% |
| 2017 Q2 | -6.4 Million SEK | -44.94% |
| 2017 Q3 | -8.28 Million SEK | -29.37% |
| 2016 FY | - SEK | 14.54% |
| 2016 Q1 | -4.28 Million SEK | -11.48% |
| 2016 Q2 | -4.66 Million SEK | -8.94% |
| 2016 Q3 | 8.9 Million SEK | 290.93% |
| 2016 Q4 | -4.82 Million SEK | -154.17% |
| 2015 Q4 | -3.84 Million SEK | 47.52% |
| 2015 Q3 | -7.31 Million SEK | -69.46% |
| 2015 Q2 | -4.31 Million SEK | 28.79% |
| 2015 Q1 | -6.06 Million SEK | -78.8% |
| 2015 FY | - SEK | -29.58% |
| 2014 Q4 | -3.39 Million SEK | 8.35% |
| 2014 Q2 | -4.53 Million SEK | 9.4% |
| 2014 Q3 | -3.7 Million SEK | 18.3% |
| 2014 Q1 | -5 Million SEK | -12.92% |
| 2014 FY | - SEK | -29.1% |
| 2013 Q1 | 851 Thousand SEK | 106.82% |
| 2013 Q4 | -4.42 Million SEK | -9.17% |
| 2013 FY | - SEK | 72.18% |
| 2013 Q3 | -4.05 Million SEK | 21.35% |
| 2013 Q2 | -5.15 Million SEK | -705.99% |
| 2012 Q1 | -13.12 Million SEK | 57.34% |
| 2012 Q4 | -12.47 Million SEK | -121.78% |
| 2012 Q2 | -15.06 Million SEK | -14.77% |
| 2012 Q3 | -5.62 Million SEK | 62.66% |
| 2012 FY | - SEK | -141.41% |
| 2011 Q1 | 96.88 Million SEK | 33.44% |
| 2011 FY | - SEK | 4180.58% |
| 2011 Q2 | 71.9 Million SEK | -25.78% |
| 2011 Q3 | -26.25 Million SEK | -136.51% |
| 2011 Q4 | -30.76 Million SEK | -17.19% |
| 2010 Q2 | -26.84 Million SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | -30.99 Million SEK | -15.45% |
| 2010 Q4 | 72.6 Million SEK | 334.24% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | -220.94% |
| Amniotics AB (publ) | -27.14 Million SEK | -418.922% |
| BioArctic AB (publ) | 275.38 Million SEK | 151.147% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 61.705% |
| Camurus AB (publ) | 562.54 Million SEK | 125.038% |
| Cantargia AB (publ) | -284.31 Million SEK | 50.46% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -619.398% |
| CombiGene AB (publ) | -35.33 Million SEK | -298.604% |
| Genovis AB (publ.) | 64.57 Million SEK | 318.13% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -22.578% |
| Mendus AB (publ) | -97.84 Million SEK | -43.952% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -280.432% |
| Intervacc AB (publ) | -68.98 Million SEK | -104.191% |
| Kancera AB (publ) | -61.88 Million SEK | -127.586% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -425.897% |
| LIDDS AB (publ) | -39.67 Million SEK | -255.057% |
| Lipum AB (publ) | -37.11 Million SEK | -279.458% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -1063.673% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 548.513% |
| NextCell Pharma AB | -40.98 Million SEK | -243.663% |
| OncoZenge AB (publ) | 7.26 Million SEK | 2038.494% |
| Saniona AB (publ) | -69.69 Million SEK | -102.096% |
| Simris Alg AB (publ) | -22.36 Million SEK | -529.839% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 55.633% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 50.059% |
| Xintela AB (publ) | -53.47 Million SEK | -163.416% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 17.056% |
| Ziccum AB (publ) | -20.34 Million SEK | -592.415% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -890.722% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -724.437% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 7042650.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 40.723% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -6671.683% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -948.701% |
| Corline Biomedical AB | -1.69 Million SEK | -8229.45% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 18.735% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -156.999% |
| Aptahem AB (publ) | -10 Million SEK | -1307.212% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 1319.595% |
| Fluicell AB (publ) | -25.91 Million SEK | -443.532% |
| Biovica International AB (publ) | -119.5 Million SEK | -17.861% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -233.58% |
| AcouSort AB (publ) | -16.7 Million SEK | -743.268% |
| Abliva AB (publ) | -93.6 Million SEK | -50.469% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 55.86% |
| 2cureX AB (publ) | -35.13 Million SEK | -300.874% |
| I-Tech AB | 30.34 Million SEK | 564.165% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 80.288% |
| Cyxone AB (publ) | -20.41 Million SEK | -589.973% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -37.479% |
| Biosergen AB | 228 Thousand SEK | 61876.754% |
| Nanologica AB (publ) | -62.11 Million SEK | -126.744% |
| SynAct Pharma AB | -222.7 Million SEK | 36.753% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -221.13% |
| BioInvent International AB (publ) | -312.7 Million SEK | 54.958% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 45622.005% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 335467.509% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 39.189% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1498.313% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -29.747% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -1128.102% |